Literature DB >> 16104538

[Appropriate dose of isobaric bupivacaine with fentanyl in spinal anesthesia for cesarean section].

Michiyo Kimoto1, Kouhei Murao, Atsuko Shirane, Sachiyo Sakamoto, Makiko Yamada, Shin-ichi Nakao, Koh Shingu.   

Abstract

BACKGROUND: Spinal anesthesia combined with fentanyl is commonly used for cesarean section. We studied the appropriate dose of isobaric bupivacaine for spinal anesthesia when combined with a fixed dose of 20 microg fentanyl.
METHODS: Forty-seven women scheduled for cesarean section were allocated into four-groups according to the dose of 0.5% isobaric bupivacaine with 20 microg fentanyl; 1.0 ml (n=5), 1.5 ml (n=11), 2.0 ml (n=11), and 2.5 ml (n=20).
RESULTS: The requirement of epidural anesthesia for pain relief or muscle relaxant was less in the 2.0 ml and 2.5 ml groups than the other groups. However, dyspnea due to high spinal anesthesia developed in 3 subjects out of 20 in the 2.5 ml group.
CONCLUSIONS: Two ml of 0.5% isobaric bupivacaine was the most appropriate dose for cesarean section, when combined with 20 microg of fentanyl.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16104538

Source DB:  PubMed          Journal:  Masui        ISSN: 0021-4892


  3 in total

1.  Lornoxicam and ondansetron for the prevention of intrathecal fentanyl-induced pruritus.

Authors:  Nurcin Gulhas; Feray Akgul Erdil; Ozlem Sagir; Ender Gedik; Turkan Togal; Zekine Begec; M Ozcan Ersoy
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

2.  Relation between fentanyl dose and patient state index during spinal anesthesia for elective cesarean section.

Authors:  Hiroki Iwata; Hiroaki Sakai; Souichiro Mimuro; Nako Uozaki; Hiromitsu Yamaguchi; Kenji Takahashi; Yoshito Shiraishi
Journal:  JA Clin Rep       Date:  2016-10-19

3.  The effects of hyperbaric or isobaric bupivacaine on bispectral index in spinal anesthesia for cesarean section.

Authors:  Mitra Jabalameli; Nina Hazegh; Saeed Gholami
Journal:  J Res Med Sci       Date:  2012-02       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.